公开(公告)号：US20190324038A1

公开(公告)日：2019-10-24

申请号：US16329751

申请日：2017-08-31

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Florent GINHOUX ,  Chi Ee Peter SEE

IPC: G01N33/569 ,  A61K35/15 ,  C07K16/28

Abstract: Biomarkers for the detection and identification of a precursor of conventional dendritic cell (cDC) (pre-DC) and its cell subsets (pre-cDC1 or pre-cDC2), are defined, which include CD169, CD327, AXL, CD271, CD324 and combinations thereof for detecting pre-DCs. Methods for detecting a disease or condition, prognosis of an existing disease or condition comprising determining the number of pre-DC cells in sample from a subject as compared to control, as well as methods of treating a patient comprising administration of antibodies against CD169, CD327, AXL, CD271, CD324 and combinations thereof are also disclosed. In addition, an immunogenic composition comprising one or more binding molecules specific for one or more biomarkers or antigen of a target disease and/or one or more cells selected from the group consisting of early pre-DC, pre-cDC1 and pre-cDC2 are also disclosed for eliciting an immune response against an infectious disease or cancer.

公开(公告)号：US20210100897A1

公开(公告)日：2021-04-08

申请号：US16610461

申请日：2018-05-03

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Florent GINHOUX ,  Chi Ee Peter SEE

IPC: A61K39/39 ,  A61K39/00 ,  A61K35/15 ,  C12N5/0784

Abstract: The present invention relates to a method of treating or preventing an infection, a neoplastic disease or an immune-related disease in a subject in need thereof, the method comprising contacting a therapeutically effective or immuno-effective amount of an TLR9 agonist, specifically CpG oligodeoxynucleotide 2216 (CpG ODN), with a precursor dendritic cell (pre-DC), wherein the TLR9 agonist stimulates the pre-DC to secrete one or more cytokines such as TNF-alpha and IL-12p40, to thereby activate or increase the subject's immune response for treating or preventing the infection, the neoplastic disease or the immune-related disease. The present invention also relates to immunogenic or adjuvant compositions comprising the TLR9 agonist. A method of diagnosing a deficient immune system in a subject, comprising contacting a sample comprising pre-DC from the subject with one or more TLR 9 agonists and kits thereof are also disclosed.